NI201300008A - THE NEW STABLE CONJUGATED POLYETHYLENE GLYCOL OF INTERFERON ALPHA, REPRESENTED BY A POSITIONAL ISOMER - Google Patents

THE NEW STABLE CONJUGATED POLYETHYLENE GLYCOL OF INTERFERON ALPHA, REPRESENTED BY A POSITIONAL ISOMER

Info

Publication number
NI201300008A
NI201300008A NI201300008A NI201300008A NI201300008A NI 201300008 A NI201300008 A NI 201300008A NI 201300008 A NI201300008 A NI 201300008A NI 201300008 A NI201300008 A NI 201300008A NI 201300008 A NI201300008 A NI 201300008A
Authority
NI
Nicaragua
Prior art keywords
conjugate
formula
polyethylene glycol
interferon
represented
Prior art date
Application number
NI201300008A
Other languages
Spanish (es)
Inventor
Veniaminovna Chernovskaya Tatyana
Alexandrovich Denisov Lev
Valentinovich Morozov Dmitriy
Georgievna Rudenko Elena
Vsevolodovna Klenova Angelina
Original Assignee
Closed Join Stock Company Biocad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45497062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201300008(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Closed Join Stock Company Biocad filed Critical Closed Join Stock Company Biocad
Publication of NI201300008A publication Critical patent/NI201300008A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención está relacionada a la industria farmacéutica y medicina, en particular, al nuevo PEG - interferón derivados y al descubrimiento de un conjugado nuevo funcional, altamente estable de interferón a polietileno glicol con una actividad interferón alfa, con inmunogenicidad reducida, con efectos biológicos prolongados y parámetros fármaco - kinéticos mejorados de fórmula general (I). También la invención está relacionada a drogas conteniendo el declarado conjugado de la fórmula (1), composiciones farmacéuticas conteniendo PEG - IFN conjugado y terapéuticamente aceptable excipientes ideales para el tratamiento de infecciones virales y cáncer, también enfermedades asociadas con inmunodeficiencia primaria o secundaria. La invención está relacionada al uso de conjugado de fórmula (1) en productos medicinales, los cuales tienen actividad antiviral, antiproliferativa e inmunomodulatoria, aproximaciones y/o tratamiento de enfermedades asociadas con inmunodeficiencia primaria o secundaria de conjugado de fórmula (1) y al contenedor con tal composición farmacéutica.The invention is related to the pharmaceutical industry and medicine, in particular, to the new PEG-interferon derivatives and to the discovery of a new functional, highly stable conjugate of interferon to polyethylene glycol with an alpha interferon activity, with reduced immunogenicity, with prolonged biological effects. and improved drug-kinetic parameters of general formula (I). The invention is also related to drugs containing the declared conjugate of formula (1), pharmaceutical compositions containing PEG-IFN conjugated and therapeutically acceptable excipients ideal for the treatment of viral infections and cancer, also diseases associated with primary or secondary immunodeficiency. The invention is related to the use of conjugate of formula (1) in medicinal products, which have antiviral, antiproliferative and immunomodulatory activity, approaches and / or treatment of diseases associated with primary or secondary immunodeficiency of conjugate of formula (1) and to the container with such a pharmaceutical composition.

NI201300008A 2010-07-20 2013-01-18 THE NEW STABLE CONJUGATED POLYETHYLENE GLYCOL OF INTERFERON ALPHA, REPRESENTED BY A POSITIONAL ISOMER NI201300008A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010129824/10A RU2447083C1 (en) 2010-07-20 2010-07-20 NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NαH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON

Publications (1)

Publication Number Publication Date
NI201300008A true NI201300008A (en) 2014-05-26

Family

ID=45497062

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201300008A NI201300008A (en) 2010-07-20 2013-01-18 THE NEW STABLE CONJUGATED POLYETHYLENE GLYCOL OF INTERFERON ALPHA, REPRESENTED BY A POSITIONAL ISOMER

Country Status (20)

Country Link
KR (1) KR101586372B1 (en)
CN (1) CN102617736B (en)
AR (1) AR087227A1 (en)
BR (1) BRPI1101565A2 (en)
CO (1) CO6680611A2 (en)
CR (1) CR20130021A (en)
CU (1) CU24193B1 (en)
DO (1) DOP2013000002A (en)
EA (1) EA020257B1 (en)
EC (1) ECSP13012398A (en)
HK (1) HK1170504A1 (en)
MX (1) MX2011007458A (en)
MY (1) MY168784A (en)
NI (1) NI201300008A (en)
PE (1) PE20131034A1 (en)
RU (1) RU2447083C1 (en)
SG (1) SG187117A1 (en)
UA (1) UA99766C2 (en)
UY (1) UY33525A (en)
WO (1) WO2012011836A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2515913C1 (en) * 2013-03-22 2014-05-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") HYBRID PROTEIN HAVING PROLONGED ACTION, BASED ON RECOMBINANT HUMAN INTERFERON ALPHA-2 (VARIANTS), METHOD OF ITS PRODUCTION AND STRAIN OF Saccharomyces cerevisiae FOR IMPLEMENTING THIS METHOD (VERSIONS)
EA021643B1 (en) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Monopegylated interferon-alpha of linear structure and a pharmaceutical composition for preparing a medicament having interferon-alpha activity
EA021610B1 (en) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Liquid antiviral formulation
CN103463623B (en) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 A kind of Peg-IFN alpha-2b injection and preparation method thereof
RU2554761C1 (en) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Anti-enteroviral and immunostimulating agent
RU2572800C1 (en) * 2014-09-22 2016-01-20 Закрытое Акционерное Общество "Биокад" New formulation containing polyethylene glycol (peg) conjugated interferon alpha-2beta characterised by less painful administration
EA029498B1 (en) * 2015-11-24 2018-04-30 Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) ANTI-TUMOUR DRUG BASED ON RECOMBINANT INTERFERON ALPHA-2b IN THE FORM OF MICROPARTICLES FOR PARENTERAL ADMINISTRATION
RU2678332C1 (en) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Pegylated interferon lambda with high bioaccessability in oral use and method for production thereof
CN114392237B (en) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 Freeze-dried virus preparation and preparation method thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
JP2758154B2 (en) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー Liquid preparations containing interferon
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
BR0314172A (en) * 2002-09-09 2005-07-26 Nektar Therapeutics Al Corp Water-soluble polymer, composition, hydrate or acetal form, compound, composition, uses of compound and conjugate, and process for preparing conjugate
RU2311930C2 (en) * 2004-04-30 2007-12-10 Закрытое акционерное общество "ВЕРОФАРМ" Pagylated interferon against viral infection
CA2572751A1 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
EP1915412B1 (en) * 2005-07-19 2010-03-24 Nektar Therapeutics Method for preparing polymer maleimides
JP2009541333A (en) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド Modified ribonuclease
CN101491682A (en) * 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 PEG-IFN omega conjugate and preparation technique thereof
CN101591387A (en) * 2008-05-28 2009-12-02 中国人民解放军军事医学科学院微生物流行病研究所 PEG-IFN omega conjugate
CN101514229B (en) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 Human interferon alpha derivative and polyethylene glycol modified substance thereof

Also Published As

Publication number Publication date
EA201100809A1 (en) 2012-01-30
RU2010129824A (en) 2012-01-27
CN102617736B (en) 2015-11-25
MY168784A (en) 2018-12-04
HK1170504A1 (en) 2013-03-01
UA99766C2 (en) 2012-09-25
CO6680611A2 (en) 2013-05-31
ECSP13012398A (en) 2013-05-31
AR087227A1 (en) 2014-03-12
RU2447083C1 (en) 2012-04-10
MX2011007458A (en) 2012-01-19
CU20130013A7 (en) 2013-04-19
UY33525A (en) 2012-02-29
CU24193B1 (en) 2016-09-30
KR20130056885A (en) 2013-05-30
SG187117A1 (en) 2013-02-28
EA020257B1 (en) 2014-09-30
WO2012011836A1 (en) 2012-01-26
PE20131034A1 (en) 2013-09-27
CR20130021A (en) 2013-02-20
BRPI1101565A2 (en) 2012-12-04
KR101586372B1 (en) 2016-01-18
CN102617736A (en) 2012-08-01
DOP2013000002A (en) 2013-09-15

Similar Documents

Publication Publication Date Title
NI201300008A (en) THE NEW STABLE CONJUGATED POLYETHYLENE GLYCOL OF INTERFERON ALPHA, REPRESENTED BY A POSITIONAL ISOMER
DOP2011000343A (en) PIRIDINE TIENO DERIVATIVES [2,3-B] AS VIRAL REPLICATION INHIBITORS
MX2012007410A (en) Novel antiviral compounds.
NI201700101A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING N - (3, 5 - DIMETOXIPHENIL) - N'- (1-METHYLETHYL) - N - [3- (1-METHYL-1H-PIRAZOL-4-IL) QUINOXALINE-6-IL] ETHANE-1 , 2-DIAMINE
MX2020003055A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use.
AR067184A1 (en) USE OF 6- (3-CHLORO-2-FLUORBENCIL) -1 - [(2S) -1-HIDROXI-3-METILBUTAN-2-IL] -7-METOXI-4-OXO-1,4-DIHYDROCHINOLINE-3- CARBOXILICO. PHARMACEUTICAL COMPOSITION
ES2916649T1 (en) Compositions and uses for the treatment of multiple sclerosis
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
SI2932970T1 (en) Antiviral therapy
MD4430C1 (en) Compositions and methods for treating hepatitis C virus
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
JP2013542247A5 (en)
BR112015011179A8 (en) stable aqueous pharmaceutical compositions comprising human insulin or an analogue or derivative thereof, their use and processes for their preparation
EA200800467A1 (en) APPLICATION OF COMPLEX ETHERS OF HYDROXYBENZOIC ACID AND ANALOGUES FOR OBTAINING MEDICINES FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTION
CR20140540A (en) NEW DOSAGE FORM AND FORMULATION OF ABEDITEROL
JO3587B1 (en) Oral dosage forms of bendamustine
AR093476A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ECTODERMAL DYSPLASIA
MX2022006940A (en) Pharmaceutical compositions comprising cabotegravir.
DOP2022000004A (en) PHARMACEUTICAL COMPOSITIONS RESISTANT TO THE DISCHARGE OF DOSES THAT INCLUDE VENIRUNAD
UY33806A (en) NOVEDOUS IMIDAZOQUINOLINE COMPOUNDS, COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF DISEASES MEDIATED BY TLR7?
MX350516B (en) Nitrogen-containing fused ring compounds for use as crth2 antagonists.
TH133837A (en)
CO2020000292A2 (en) Combined medicinal preparation to treat viral infections
RU2014116988A (en) ALISPORIVIR FOR TREATING INFECTIONS CAUSED BY HEPATITIS C VIRUS
EA202091320A1 (en) LOCAL APPLICATION OF DIOXIDINE FOR INFECTIOUS INFLAMMATORY LESIONS OF THE EPITHELIUM